Tags

Type your tag names separated by a space and hit enter

The medical therapy of reflux oesophagitis.
Baillieres Clin Gastroenterol 1987; 1(4):791-807BC

Abstract

Besides changes in behaviour and lifestyle we nowadays have the choice of specific drugs in the treatment of reflux oesophagitis. A distinction can be made in motility modulating drugs, which stimulate oesophageal peristalsis and LOS pressure, mucosa-protecting drugs, which form a protective layer on the oesophageal mucosa, acid neutralizing (antacids) and acid suppressing drugs (H2-receptor antagonists, omeprazole). So far the results of medical therapy of reflux oesophagitis are still suboptimal. Giving the H2-receptor antagonists with the evening meal would possibly be more appropriate. A valid alternative is the mucosa-protecting agent sucralfate. Monotherapy will probably be insufficient for full healing, which explains why trials of combination therapy (H2-receptor antagonists plus sucralfate or plus cisapride) are being conducted. If omeprazole becomes available, it will revolutionize the therapy of severe reflux oesophagitis. Many questions (dose, duration, maintenance, safety monitoring etc.) remain to be determined.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

2896523

Citation

Tytgat, G N., and C Y. Nio. "The Medical Therapy of Reflux Oesophagitis." Bailliere's Clinical Gastroenterology, vol. 1, no. 4, 1987, pp. 791-807.
Tytgat GN, Nio CY. The medical therapy of reflux oesophagitis. Baillieres Clin Gastroenterol. 1987;1(4):791-807.
Tytgat, G. N., & Nio, C. Y. (1987). The medical therapy of reflux oesophagitis. Bailliere's Clinical Gastroenterology, 1(4), pp. 791-807.
Tytgat GN, Nio CY. The Medical Therapy of Reflux Oesophagitis. Baillieres Clin Gastroenterol. 1987;1(4):791-807. PubMed PMID: 2896523.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The medical therapy of reflux oesophagitis. AU - Tytgat,G N, AU - Nio,C Y, PY - 1987/10/1/pubmed PY - 1987/10/1/medline PY - 1987/10/1/entrez SP - 791 EP - 807 JF - Bailliere's clinical gastroenterology JO - Baillieres Clin. Gastroenterol. VL - 1 IS - 4 N2 - Besides changes in behaviour and lifestyle we nowadays have the choice of specific drugs in the treatment of reflux oesophagitis. A distinction can be made in motility modulating drugs, which stimulate oesophageal peristalsis and LOS pressure, mucosa-protecting drugs, which form a protective layer on the oesophageal mucosa, acid neutralizing (antacids) and acid suppressing drugs (H2-receptor antagonists, omeprazole). So far the results of medical therapy of reflux oesophagitis are still suboptimal. Giving the H2-receptor antagonists with the evening meal would possibly be more appropriate. A valid alternative is the mucosa-protecting agent sucralfate. Monotherapy will probably be insufficient for full healing, which explains why trials of combination therapy (H2-receptor antagonists plus sucralfate or plus cisapride) are being conducted. If omeprazole becomes available, it will revolutionize the therapy of severe reflux oesophagitis. Many questions (dose, duration, maintenance, safety monitoring etc.) remain to be determined. SN - 0950-3528 UR - https://www.unboundmedicine.com/medline/citation/2896523/The_medical_therapy_of_reflux_oesophagitis_ L2 - https://medlineplus.gov/gerd.html DB - PRIME DP - Unbound Medicine ER -